STOCK TITAN

Cronos Group Stock Price, News & Analysis

CRON Nasdaq

Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.

Cronos Group Inc. (CRON) is a global leader in cannabis innovation, operating across medicinal and recreational markets with brands like Peace Naturals and Spinach. This page provides investors and industry observers with centralized access to official press releases, financial updates, and strategic developments.

Track CRON's progress through earnings reports, regulatory milestones, product launches, and partnership announcements. Our curated news collection ensures you stay informed about operational expansions, research breakthroughs, and market positioning in the evolving cannabis sector.

All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of CRON's performance across North American, European, and Australian markets.

Rhea-AI Summary

Cronos Group Inc. reported a 23% increase in consolidated net revenue for Full Year 2022, reaching $91.9 million, compared to $74.4 million in 2021. The company's net revenue in Israel surged 128%, significantly boosting overall performance. In Q4 2022, net revenue was $22.9 million, a decline of 11% year-over-year due to lower sales in the U.S. The company ended 2022 with $878 million in cash and short-term investments. Notably, Spinach® became the top edible brand in Canada as of January 2023. The CEO emphasized cost-saving measures yielding $28.7 million savings in 2022, with an additional anticipated savings of $10-20 million in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) has announced its conference call for the 2022 fourth quarter and full-year earnings on February 28, 2023, at 8:30 a.m. ET. The call aims to provide insights into the Company’s financial results and allow for questions from the investment community. Participants can register for the call online to ensure timely access. The company is committed to advancing cannabis research and product development across its international brand portfolio, which includes Spinach®, PEACE NATURALS®, and Lord Jones®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary

Cronos Group Inc. has announced that its Spinach® gummies have achieved the status of the top-selling edible brand in Canada, commanding a 15.8% market share of the total edibles category as of January 2023. Launched in 2021, Spinach® includes SOURZ by Spinach™ and Spinach FEELZ™, both recognized for their unique flavors and proprietary technology. Cronos expects this success to bolster its market presence and support future product innovations. This achievement is seen as a validation of Cronos' innovation and marketing strategies as it aims to expand its product lineup globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none
Rhea-AI Summary

Cronos Group Inc. announced the voluntary relinquishment of a warrant by Altria Group's subsidiary, Altria Summit LLC, allowing the purchase of up to 84,243,223 common shares at C$19.00 per share. This decision was made on December 16, 2022, without any financial consideration. Despite this, Altria retains ownership of 156,573,537 common shares and four board designees, ensuring continued influence. The relinquishment does not alter Altria's rights under the Investor Rights Agreement established in 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
none
-
Rhea-AI Summary

Cronos Group has launched its innovative Spinach FEELZ™ THC+CBC Day Trip Mango Lime gummies, marking the first CBC gummy product in Canada.

Featuring a unique 3:1 ratio of CBC to THC, these gummies are available in Alberta and British Columbia, with plans for wider distribution.

The product contains 10mg of THC and 30mg of CBC per pack, targeting adults seeking enhanced experiences. Cronos is set to issue approximately 489,000 common shares to Ginkgo Bioworks for the commercialization of CBC, reflecting a strategic partnership for cannabinoid development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary

Cronos Group, a leading global cannabinoid company, will have its CEO, Mike Gorenstein, speaking at the Stifel Canada’s 3rd Annual Future of Healthcare Conference on December 7, 2022, at 1:00 p.m. ET. The event will be available via webcast on Cronos' Investor website. The company is focused on innovative cannabis research and technology, developing an iconic brand portfolio that includes Spinach®, PEACE NATURALS®, Lord Jones®, Happy Dance®, and PEACE+®. For more information, visit thecronosgroup.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) announced the appointment of James Holm as Chief Financial Officer, effective immediately, succeeding Bob Madore. Holm has nearly two decades of experience in finance, having previously worked at Vertiv, Worldpay, and Procter & Gamble. CEO Mike Gorenstein emphasized Holm's strategic thinking and financial expertise, which are expected to enhance Cronos' margin expansion and revenue growth strategies. Holm expressed enthusiasm for joining Cronos and contributing to the company's growth initiatives, signaling a potential positive shift in financial leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
management
-
Rhea-AI Summary

Cronos Group announced its Q3 2022 results, with consolidated net revenue rising 3% YoY to $20.9 million, driven by an 88% increase in Israeli revenue. Adjusted EBITDA improved by $25.1 million YoY, indicating operational efficiencies. The company aims for $20-$25 million in operating expense savings for 2022. Notable product successes include SOURZ by Spinach™, a top edible in Canada. However, U.S. revenue fell by 76% to $514, and net income declined significantly. The appointment of Jeff Jacobson as Chief Growth Officer signals a focus on growth strategies moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.42%
Tags
-
Rhea-AI Summary

Cronos Group has reached final settlement agreements with the SEC and the OSC regarding investigations into its previously disclosed financial statement restatements. The SEC's settlement, issued on October 24, 2022, imposes a cease-and-desist order but does not involve any civil penalties. Concurrently, the OSC requires Cronos to pay C$1.34 million and acknowledges non-compliance with Ontario's Securities Act. Additionally, Cronos will have restrictions on private offering exemptions for five years and will retain an independent consultant to improve its internal controls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) will host its 2022 third quarter earnings conference call on November 7, 2022, at 8:30 a.m. ET. Senior management will present the financial results and answer questions from investors after prepared remarks. Participants are encouraged to register online and dial in 15 minutes early to avoid delays. The conference call will be archived for replay on the company’s website. Cronos is focused on innovative cannabinoid research and product development, with a diverse international brand portfolio including Spinach®, Lord Jones®, and PEACE NATURALS®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags

FAQ

What is the current stock price of Cronos Group (CRON)?

The current stock price of Cronos Group (CRON) is $1.85 as of May 6, 2025.

What is the market cap of Cronos Group (CRON)?

The market cap of Cronos Group (CRON) is approximately 700.0M.
Cronos Group

Nasdaq:CRON

CRON Rankings

CRON Stock Data

700.03M
200.59M
46.39%
14.32%
1.19%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
Canada
STAYNER